What is the recommended treatment for idiopathic intracranial hypertension (IIH)?

IIH Treatment

The treatment of idiopathic intracranial hypertension centers on three pillars: weight loss (the only disease-modifying therapy), acetazolamide for reducing intracranial pressure, and surgical intervention when vision is threatened. 1

First-Line Management: Weight Loss + Acetazolamide

Weight Loss

• Weight reduction is the cornerstone of IIH management and the only intervention that addresses the underlying disease process 1
• Even modest weight loss can lead to disease remission in most patients 2
• Bariatric surgery should be considered for appropriate candidates as it provides sustained weight reduction 3

Acetazolamide Dosing

• Start with 250-500 mg twice daily and titrate upward 1
• Target dose is up to 4 g daily (though only 44% of patients tolerate this maximum dose; most tolerate 1 g/day) 1
• Warn patients about common side effects: diarrhea, metallic taste (dysgeusia), fatigue, nausea, paresthesias, tinnitus, vomiting, depression, and rarely renal stones 1
• Important caveat: Acetazolamide has NOT been shown effective for headache alone—it works by reducing intracranial pressure 1

Alternative Medical Therapy: Topiramate

• Consider topiramate as an alternative, starting at 25 mg and escalating weekly to 50 mg twice daily 1
• Has dual benefit: carbonic anhydrase activity AND appetite suppression 1
• Critical counseling points for women:
  • Reduces efficacy of oral contraceptives
  • Teratogenic risks
  • Side effects include depression and cognitive slowing 1

Headache Management (Separate from ICP Reduction)

Acute Headache Treatment

• Short-term use only: NSAIDs or paracetamol in the first few weeks 1
• Indomethacin may have advantage due to ICP-lowering effects 1
• Never prescribe opioids for IIH headaches 1
• Provide gastric protection with NSAIDs 1

Preventing Medication Overuse Headache

• Educate immediately about medication overuse headache risk (>15 days/month of simple analgesics OR >10 days/month of opioids/triptans/combinations) 1
• This is a common pitfall that prevents optimization of preventative treatments 1

Migraine-Pattern Headaches (68% of IIH patients)

• For acute migraine attacks: triptans + NSAID or paracetamol + antiemetic with prokinetic properties 1
• Limit triptan use to 2 days/week or maximum 10 days/month 1
• Consider migraine preventatives early (take 3-4 months to reach maximal efficacy), especially once papilledema resolves 1
• Implement lifestyle modifications: limit caffeine, regular meals, adequate hydration, exercise, sleep hygiene, stress management (yoga, CBT, mindfulness) 1

What NOT to Do

• Serial lumbar punctures are NOT recommended for IIH management—relief is short-lived (CSF replaces at 25 mL/hour) and causes anxiety and back pain 1
• Lumbar punctures are not effective for headache treatment alone 1

Surgical Intervention: When Vision is Threatened

Indications for Surgery

• Progressive visual field loss despite medical therapy
• Fulminant IIH with rapid vision deterioration
• Medically refractory cases with visual compromise

Surgical Options (in order of preference based on evidence)

1. Venous Sinus Stenting (First-Line Surgical Option)

• Best outcomes for headache resolution and visual improvement with lowest failure rate (11.3%) and severe complication rate (2.3%) 3
• Improves papilledema in 87.1%, visual fields in 72.7%, headaches in 72.1% 3
• Requires long-term antithrombotic therapy (>6 months) 1
• Complications: ipsilateral headache (common, short-lived), stent-adjacent stenosis requiring retreatment (33%), rarely vessel perforation/subdural hematoma/stent migration/thrombosis 1

2. Ventriculoperitoneal (VP) Shunt (Preferred CSF Diversion)

• VP shunt preferred over LP shunt due to lower revision rates per patient 1
• Use neuronavigation for placement 1
• Use adjustable valves with antigravity or antisiphon devices to reduce low-pressure headaches 1
• Significant limitations: 34% worsen at 1 year, 45% at 3 years; fails to improve headache in one-third to one-half 1
• Severe complication rate 9.4%, failure rate 43.4% 3
• UK patients must inform Driver and Vehicle Licensing Agency after VP shunt placement 1

3. Optic Nerve Sheath Fenestration (ONSF)

• Consider for fulminant cases or asymmetric papilledema with unilateral vision loss 1
• Improves papilledema in 90.5%, visual fields in 65.2%, headaches in 49.3% 3
• Lower complication rate than CSF diversion (2.2% severe complications, 9.4% failure rate) 3
• Temporary effects: double vision, anisocoria, optic nerve head hemorrhages 1
• Rare permanent complications: branch/central retinal artery occlusions 1
• Must be performed by experienced clinician 1

Treatment Algorithm Summary

1. All patients: Weight loss counseling + lifestyle modifications
2. Medical therapy: Acetazolamide 250-500 mg BID, titrate up (or topiramate if acetazolamide not tolerated)
3. Headache management: Phenotype-specific treatment, avoid medication overuse
4. Vision threatened: Venous sinus stenting (first-line surgical) > VP shunt > ONSF
5. Monitor: Regular ophthalmologic assessment for papilledema and visual fields

Critical pitfall: Do not rely on serial LPs, do not prescribe opioids, and educate about medication overuse headache from the first visit 1